Top 10 Retail Companies To Buy Right Now

Top 10 Retail Companies To Buy Right Now: Express Scripts Holding Co (ESRX)

Express Scripts Holding Company, incorporated in 2011, provides healthcare management and administration services on behalf of its clients, which include health maintenance organizations (HMOs), health insurers, third-party administrators, employers, union-sponsored benefit plans, workers compensation plans, and government health programs. The Company operates in two segments: Pharmacy Benefit Management (PBM) and Emerging Markets (EM). PBM services include network claims processing, home delivery services, patient care and direct specialty and fertility home delivery to patients, benefit plan design consultation, drug utilization review, formulary management, drug data analysis services, distribution of injectable drugs to patients homes and physicians offices, bio-pharma services, and fulfillment of prescriptions to low-income patients through manufacturer-sponsored patient assistance programs. EM segment provides distribution of pharmaceuticals and medical supplies to p roviders and clinics, healthcare account administration and implementation of consumer-directed healthcare solutions. In September 2013, it announced the acquisition of the SmartD Medicare Prescription Drug Plan (PDP).

On July 20, 2011, Express Scripts, Inc. (ESI) entered into a merger agreement (the Merger Agreement) with Medco Health Solutions, Inc. (Medco). During the year ended December 31, 2011, it reorganized its FreedomFP line of business from its EM segment into its PBM segment. On April 2, 2012, the Company completed the Merger Agreement, and after which ESI and Medco became the wholly owned subsidiaries of the Company. The Companys customers include HMOs, health insurers, third-party administrators, employers, union-sponsored benefit plans, government health programs, office-based oncologists, renal dialysis clinics, ambulatory surgery centers, primary care physicians, retina specialists and others.

Advisors' Opinion:!

• [By Ben Levisohn]

  Gilead was pilloried again yesterday for developing a drug (Sovaldi) with the highest efficacy and fewest side effects, but at a high (but not the highest) price for a new HCV therapy. The cost-benefit ratio suggests it is not the most expensive therapy in the HCV space. While the politics of Washington are not surprising, the fact that a pharmacy distribution company [Express Scripts (ESRX)] would make what we consider to be political statements is damaging to the industry and patients they serve. They, better than us, understand the benefits of Sovaldi. We view these statements as noise and believe that Sovaldi and next-generation Ledipasvir/Sovaldi represent real pharmaco (economic) value in the HCV space.

• [By Lu Wang]

  Express Scripts Holding Co. (ESRX) declined 4.5 percent to $60.88, the lowest since May. The largest U.S. processor of prescription drug claims reduced its 2013 cash flow forecast, citing delays in some non-client integration activities.

• [By Adam Levine-Weinberg]

  Strong results, modest outlook
  Rite Aid's profit was driven by three major one-time or short-term impacts. First, the company gained a number of new customers from Walgreen's dispute with pharmacy benefits manager Express Scripts (NASDAQ: ESRX  ) . Walgreen's stores rejoined the Express Scripts network as of Sept. 15, and customers are beginning to trickle back, but Rite Aid still saw a significant benefit from the dispute in fiscal year 2013. On Rite Aid's Thursday morning conference call, executives estimated the full-year benefit at $70 million-- more than half of the company's fiscal year 2013 profit.

• [By Ben Levisohn]

  Express Scripts (ESRX) has fallen 2.7% to $62 in after-hours trading after it reported a profit of $1.08, in line with analyst forecasts, but said the fourth quarter would come in between $109 and $1.13. Analyst had forecast $1.12.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-retail-companies-to-buy-right-now.html